Clinical trial data reveals that more than 70% of patients treated with a novel oral GLP-1 receptor agonist achieved clinically meaningful improvements in both HbA1c reduction and weight loss simultaneously—a dual-endpoint success rate that matches or exceeds established injectable formulations.
Comparative analysis demonstrates the oral medication’s competitive profile: 72% of oral GLP-1 recipients achieved HbA1c reduction of at least 1.0% and weight loss of 5% or greater, compared to 69% for injectable semaglutide and 75% for injectable tirzepatide. These results substantially outperform conventional monotherapy approaches, with SGLT2 inhibitors and DPP-4 inhibitors achieving dual-endpoint success in only 38% and 22% of patients, respectively.
The data underscore the therapeutic potential of oral GLP-1 agents to deliver injectable-level efficacy with improved patient acceptability, potentially transforming first-line treatment strategies for type 2 diabetes management.
Read the full article on GMJ Newsroom.
Was this article helpful?
